43 results about "Activating transcription factor" patented technology

The invention discloses a plasmid carrier pair and immune cells modified by the same, and an application thereof in preparation of drugs for local secretion of IL12 or regulating expression of IL12 and preparation of drugs for enhancing the killing effect of CAR-T cells, and also discloses a composition and combined drug box of the immune cells and the CAR-T cells. The plasmid vector pair includesa first carrier and a second carrier, the first carrier contains a Notch core, and other coding nucleic acid molecules of extracellular and intracellular segments, wherein the intracellular segment preferably contains transcription activating factors; the second carrier contains nucleic acid molecules specifically recognizing and binding with the intracellular segment in the first carrier and nucleic acid molecules encoding IL12. The combined drug box comprises a drug box A containing the immune cells and a drug box B containing the CAR-T cells. The immune cells can control the expression andsecretion of IL12, and have the effect of synergistically treating tumors with the CAR-T cells.

The invention relates to the field of cell culture technology. It concerns the knockdown, using RNA interference, or gene knockout, of activating transcription factor 6 beta (ATF6B), or the combination of ceramide synthase 2 (CERS2) and TBC1 domain family member 20 (TBC1 D20) proteins, which play central roles in the cellular secretion pathway. This downregulation leads to improved secretion of biopharmaceutically relevant products produced in mammalian cells. The invention specifically relates to mammalian cells having enhanced secretion of a recombinant therapeutic protein compared to a control cell, a method of producing said mammalian cell, a method for the production of a recombinant secreted therapeutic protein and the use of said mammalian cell for increasing the yield of a recombinant secreted therapeutic protein.

The invention provides an application of dermal fibroblasts in the treatment of melanoma, which belongs to the technical field of biomedicine. Through research, the present invention finds that in vitro, dermal fibroblasts expressing a high level of activating transcription factor 3 can inhibit the proliferation and migration of melanoma cells, accompanied by the downregulation of different cytokines (including IL‑6). In vivo, dermal fibroblasts with high expression of activator transcription factor 3 reduced tumor formation. Addition of recombinant IL‑6 to melanoma cells reversed those in vitro and in vivo effects, suggesting that activating transcription factor 3 expression in dermal fibroblasts regulates melanoma progression through the IL‑6 / STAT3 pathway, with promising practical applications value.

Compounds as inhibitors of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.

The invention provides a progesterone whole-cell biosensor as well as a preparation method and application thereof. The invention designs a design strategy of a non-natural transcription factor DLA based on a tiny conformation change of a ligand binding domain LBD after a target molecule is combined with a receptor of the target molecule. A simulation result shows that a pronucleus LexA, a truncated LBD from a progestational hormone receptor and a pronucleus B42 jointly form the DLA with a transcription factor function. In order to verify the effectiveness of the design, DLA is used as a transcription activating factor for controlling green fluorescent protein transcription, and a progesterone specific whole-cell biosensor is successfully constructed, and the sensitivity index (EC50) of the progesterone specific whole-cell biosensor is 27 [mu] g / L and reaches the clinical detection level. According to the present invention, the scientific, accurate and rapid progesterone content detection method is established, and the method is particularly suitable for direct detection of trace progesterone in the sample, and is the progesterone microbiological detection method with the progesterone microbiological detection method with the progesterone microbiological detection prospect.